nuclear receptor subfamily 2 group E member 3Genealiases: ESCS · ESCS1 · PNR · RNR · RP37 · rd7
Q-omics provides the consensus-scored NR2E3 profile across patient tissues and cancer cell-line models. NR2E3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NR2E3 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, NR2E3 RNA expression shows 15,248 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LUAD, and THYM as cancer lineages where NR2E3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR2E3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR2E3 survival associations across molecular data types. NR2E3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR2E3 RNA expression–survival associations across cancer types. High NR2E3 expression shows unfavorable associations in KIRC, COAD, UVM, ACC and BLCA, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NR2E3 RNA expression.
This table summarizes NR2E3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for NR2E3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR2E3 shows lower tumor expression in LUAD, THCA, LUSC and PAAD and higher tumor expression in KICH and LIHC. The LUAD box plot shows higher NR2E3 RNA expression in normal versus tumor tissue (log2 FC = −0.282, t-test p < 0.001).
This table shows molecular features associated with NR2E3 in patient tissues and cancer cell lines. In patient samples, NR2E3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NR2E3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in STOMACH.
